Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Neuro-Metabolic Ageing Drives Diabetes-Associated Neurodegeneration: A Geroscience and Network Pharmacology Perspective.

Created on 18 Aug 2026

Authors

Sakshi Tiwari, Bilal Siddiqui, Saman Fatima, Monica Saifi, Imran A Khan, M Z Abdin

Published in

Ageing research reviews. Pages 103308. Aug 17, 2026. Epub Aug 17, 2026.

Abstract

Ageing destabilizes metabolic and neuronal regulatory networks, increasing vulnerability to type 2 diabetes (T2D) and neurodegenerative disorders. These conditions are not independent disease entities but interconnected manifestations of accelerated neuro-metabolic ageing, driven by convergent impairments in insulin signaling, nutrient sensing, mitochondrial bioenergetics, redox homeostasis, proteostasis, and chronic inflammation - processes mediated through conserved hubs including AMPK, mTOR, SIRT1, GSK3β, and NF-κB. Therapeutic strategies targeting isolated molecular lesions or late-stage pathology have consequently shown limited success in preserving cognitive and metabolic function. With T2D projected to affect 643 million people by 2030, this review adopts a geroscience framework to examine the neuro-metabolic axis as a systems-level ageing process. By integrating mechanistic insights, network pharmacology, and translational evidence, it highlights how ageing-associated network collapse drives the reciprocal reinforcement of metabolic dysfunction and neurodegeneration. Within this context, phytochemicals are repositioned not as alternative therapeutics but as biologically informative multi-node modulators illustrating the feasibility of stabilizing ageing-regulatory networks through coordinated pathway engagement. Experimental and clinical evidence indicates that phytochemicals engage conserved ageing hubs spanning insulin-IGF signaling, AMPK-mTOR nutrient sensing, redox regulation, and mitochondrial quality control - exemplified by berberine via AMPK, curcumin via NF-κB, and resveratrol via SIRT1. Translational impact remains variable, reflecting constraints of bioavailability, pharmacokinetics, and clinical heterogeneity, underscoring the need for ageing-aware models and stratified trial designs. Collectively, this review reframes diabetes-associated neurodegeneration as a consequence of neuro-metabolic ageing and argues that effective intervention must prioritize preservation of network resilience over correction of isolated disease endpoints. Aligning therapeutic strategies with the biology of ageing itself offers a more realistic pathway toward sustaining metabolic flexibility, neuronal integrity, and cognitive health across the ageing trajectory.

PMID:
42607934
Bibliographic data and abstract were imported from PubMed on 18 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement